Abstract
PurposePrevious studies have reported that psychological and social distresses associated with a cancer diagnosis have led to an increase in suicides compared to the general population. We sought to explore lung cancer-associated suicide rates in a large national database compared to the general population, and to the three most prevalent non-skin cancers [breast, prostate and colorectal cancer (CRC)].MethodsThe Surveillance, Epidemiology and End Results (SEER) database (1973–2013) was retrospectively reviewed to identify cancer-associated suicide deaths in all cancers combined, as well as for each of lung, prostate, breast or CRCs. Suicide incidence and standardised mortality ratio (SMR) were estimated using SEER*Stat-8.3.2 program. Suicidal trends over time and timing from cancer diagnosis to suicide were estimated for each cancer type.ResultsAmong 3,640,229 cancer patients, 6,661 committed suicide. The cancer-associated suicide rate was 27.5/100,000 person years (SMR = 1.57). The highest suicide risk was observed in patients with lung cancer (SMR = 4.17) followed by CRC (SMR = 1.41), breast cancer (SMR = 1.40) and prostate cancer (SMR = 1.18).Median time to suicide was 7 months in lung cancer, 56 months in prostate cancer, 52 months in breast cancer and 37 months in CRC (p < 0.001).We noticed a decreasing trend in suicide SMR over time, which is most notable for lung cancer compared to the other three cancers. In lung cancer, suicide SMR was higher in elderly patients (70–75 years; SMR = 12), males (SMR = 8.8), Asians (SMR = 13.7), widowed patients (SMR = 11.6), undifferentiated tumours (SMR = 8.6), small-cell lung cancer (SMR = 11.2) or metastatic disease (SMR = 13.9) and in patients who refused surgery (SMR = 13).ConclusionThe cancer-associated suicide rate is nearly twice that of the general population of the United States of America. The suicide risk is highest among the patients with lung cancer, particularly elderly, widowed, male patients and patients with unfavourable tumour characteristics. The identification of high-risk patients is of extreme importance to provide proper psychological assessment, support and counselling to reduce these rates.
Highlights
Recent advances in cancer treatment have focused on improving response, and survival
The suicide risk is highest among the patients with lung cancer, elderly, widowed, male patients and patients with unfavourable tumour characteristics
The shortest median time to suicide among identified anatomical sites occurred in thoracic malignancy followed by brain/central nervous system tumours and gastro-intestinal tract malignancies, while the longest was in breast cancer followed by male genital tract malignancy (Figure 1)
Summary
Recent advances in cancer treatment have focused on improving response, and survival. In 2002, the National Institutes of Health State-of-the-Science Conference panel issued a statement concerned with pain, depression and fatigue symptoms in cancer patients. The conclusion was based on studies that implicated depression as a leading cause for disability in the population above 15 years of age Their recommendations were based on the fact that the benefits of screening programmes are effective enough to outweigh the harms if paired with adequate interventional programmes. The American College of Surgeons Commission on Cancer (CoC) included survivorship care plans in cancer treatment programmes seeking CoC accreditation Their plans included surveillance, evaluation and treatment of medical and psychosocial consequences, and the screening and promotion of healthy behaviours, according to the recommendation of the Institute of Medicine, the Lance Armstrong Foundation and the National Coalition for Cancer Survivorship [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
